Trial record 2 of 5 for:
Open Studies | (insect OR mosquito OR bee) AND (bites OR stings)
Comparative Study of Two Forms of Topical Dexchlorpheniramine Maleate (Cream Versus Gel) for Insect Bites
The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2010 by Mantecorp Industria Quimica e Farmaceutica Ltd..
Recruitment status was Not yet recruiting
Recruitment status was Not yet recruiting
Sponsor:
Mantecorp Industria Quimica e Farmaceutica Ltd.
Information provided by:
Mantecorp Industria Quimica e Farmaceutica Ltd.
ClinicalTrials.gov Identifier:
NCT01233934
First received: November 2, 2010
Last updated: NA
Last verified: November 2010
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Insect bite related symptoms (pruritus and papules) are caused by the release of histamine by mast cells in the skin. Topical anti-histaminics can be used to promote relief of these symptoms. Dexchlorpheniramine maleate 1% cream is a topical anti-histaminic formulation approved by ANVISA in Brazil for the relief of skin irritation and allergies, including the ones caused by insect bites. The aim of the present study is to demonstrate non-inferiority of a new pharmacological preparation of dexchlorpheniramine maleate (1% gel) with the standard preparation (1% cream) for the relief of insect bite related symptoms and to demonstrate the safety of both preparations.
| Condition | Intervention | Phase |
|---|---|---|
|
Insect Bites |
Drug: Dexchlorpheniramine 1% Gel Drug: Dexchlorpheniramine 1% Cream |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Mantecorp Industria Quimica e Farmaceutica Ltd.:
Primary Outcome Measures:
- Pruritus Intensity at Insect Bite Site, Evaluated With a 10 Point Visual Analogic Scale (VAS) [ Time Frame: 7 days ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Composite Clinical Evaluation of Erythema, Pruritus and Papule Formation, Performed by the Investigator Using a 4-point Scale for Each One of the Parameters (Absent, Mild, Moderate, Intense). This Evaluation Constitutes the Insect Bite Score. [ Time Frame: 7 days ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 90 |
| Study Start Date: | February 2011 |
| Estimated Study Completion Date: | July 2011 |
| Estimated Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Dexchlorpheniramine 1% Cream |
Drug: Dexchlorpheniramine 1% Cream
Small amount applied over the lesion twice a day for 7 days.
|
| Experimental: Dexchlorpheniramine 1% Gel |
Drug: Dexchlorpheniramine 1% Gel
Small amount applied over the lesion twice a day for 7 days.
|
Eligibility| Ages Eligible for Study: | 2 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Presence of papules resulting from insect bites within the last 72 hours;
- Presence of symmetric lesions to compare one side to the other;
- Compliance of the subject to the treatment protocol;
- Agreement with the terms of the informed consent by the participants or their legal guardians when younger than 18 years old.
Exclusion Criteria:
- Pregnancy or risk of pregnancy;
- Lactation;
- Use of topical or systemic anti-inflammatory, anti-histaminics or immunosuppressive drugs within the last 48 hours prior to the study;
- History of atopy or allergic diseases;
- History of allergy of any component of the formulations;
- Other conditions considered by the investigator as reasonable for non-eligibility.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01233934
Contacts
| Contact: Sergio Schalka, MD | 551136811334 | medci004@terra.com.br |
Locations
| Brazil | |
| Medcin Instituto da Pele Ltda. | Not yet recruiting |
| Osasco, São Paulo, Brazil, 06023000 | |
| Principal Investigator: Sergio Schalka, MD | |
Sponsors and Collaborators
Mantecorp Industria Quimica e Farmaceutica Ltd.
More Information
No publications provided
| Responsible Party: | Celso Sustovich, Medical Director |
| ClinicalTrials.gov Identifier: | NCT01233934 History of Changes |
| Other Study ID Numbers: | ERP 185v3-10 |
| Study First Received: | November 2, 2010 |
| Last Updated: | November 2, 2010 |
| Health Authority: | Brazil: National Committee of Ethics in Research |
Keywords provided by Mantecorp Industria Quimica e Farmaceutica Ltd.:
|
Insect bites Dexchlorpheniramine Gel Cream |
Additional relevant MeSH terms:
|
Insect Bites and Stings Bites and Stings Poisoning Substance-Related Disorders Dexchlorpheniramine Chlorpheniramine Histamine H1 Antagonists Histamine Antagonists Histamine Agents |
Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs Anti-Allergic Agents Therapeutic Uses Antipruritics Dermatologic Agents |
ClinicalTrials.gov processed this record on May 23, 2013